News

Catch up on the biggest clinical updates, expert insights, and exclusive interviews from Elevate-Derm Summer 2026 in San Diego, California.

In this edition of The Practice Playbook, learn incident-to rules, Mohs coding limits, NPI liability, and how audits and whistleblowers trigger FCA cases.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Catch Up on Coverage From Day 5 of the 3rd Annual Elevate-Derm Summer Conference

As we wrap up UV Safety Awareness Month, Kathleen Suozzi, MD, explains warning signs of sun damage, sunscreen myths, and new year-round protection tools—plus the newly FDA-approved bemotrizinol.

Catch Up on Coverage From Day 4 of the 3rd Annual Elevate-Derm Summer Conference

Catch Up on Coverage From Day 3 of the 3rd Annual Elevate-Derm Summer Conference

Faculty at Elevate-Derm Summer 2026 discussed the expanding role of oral JAK inhibitors in pediatric dermatology, emphasizing earlier intervention, individualized patient selection, safety monitoring, and family-centered counseling.

Advances in vitiligo, hidradenitis suppurativa, and hair loss were among the key trends Chantel Hillstead, APRN, said APPs should watch.

Lisa Swanson, MD, discussed strategies for counseling patients on JAK inhibitor safety and where she sees the drug class expanding next in a recent Dermatology Times interview.

Learn more about the in-depth topics covered in the July 2026 digital issue of Dermatology Times.

In July's letter from the editor in chief, Christopher Bunick, MD, PhD, breaks down why dermatology clinicians should be skilled in wound care.

Oyetewa Asempa, MD, discussed the importance of scalp examination, trichoscopy, and culturally informed communication when evaluating patients with hair loss during a recent Dermatology Times interview

Victoria Garcia Albea, NP, discussed safety monitoring, patient selection, and laboratory screening considerations for oral JAK inhibitors at Elevate-Derm summer 2026

Catch Up on Coverage From Day 2 of the 3rd Annual Elevate-Derm Summer Conference

At Elevate Derm, Lisa Swanson, MD, discussed earlier oral JAK inhibitor use for alopecia areata and selecting appropriate patients.

Two phase 3 trials of Pfizer's ritlecitinib met co-primary end points for facial and total repigmentation in nonsegmental vitiligo at week 52, prompting plans for global regulatory filings.

In this Cosmetics Conundrums column, learn why the cosmeceutical vehicle drives 80% of skin care results, shaping feel, film, and active delivery for visible benefits.

RAD 2026 experts unpacked new IL-13, JAK, STAT6 and OX40 options, CHE and pediatric gaps, plus overlooked comorbidities shaping AD care.

Jane Yoo, MD, MPP, FAAD, shares expert tips to treat melasma in skin of color regarding sunscreen shades, hydroquinone breaks, TXA choices, and safer laser/peel decisions.

Karen McGuire, PhD, CEO and co-founder of BioMendics, discusses why epidermolysis bullosa simplex remains a difficult gene therapy target.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Aaron Farberg, MD, discusses how Isoclear aims to deliver isotretinoin directly to the skin through a customizable compounded topical system while avoiding the monitoring requirements associated with oral therapy.

San Diego meeting highlights inflammatory dermatoses, skin cancer, alopecia, and emerging therapeutic advances

July's FDA news was quiet, but an infant AD filing, JAK-refractory alopecia data, and a new device clearance hint at what's next.

Catch Up on Coverage From Day 1 of the 3rd Annual Elevate-Derm Summer Conference

Dermatology Times is looking back on the top stories in dermatology from the month of July.

In the latest episode of Don't Be Rash, host Andrew Krakowski, MD, is joined by Raegan D. Hunt, MD, PhD, to discuss newborn skin barrier development, umbilical cord care, and evidence-based product selection.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of July.

Phase 1 results show Bambusa Therapeutics’ BBT001 quickly reduces atopic dermatitis and itch, sustains type 2 biomarker suppression, and may enable quarterly dosing.